All In Biotech

Drug Trial Radar · NCT00073528

Study Comparing Lapatinib (GW572016) And Letrozole Versus Letrozole In Subjects With Advanced Or Metastatic Breast Cancer

A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase III Study Comparing GW572016 and Letrozole Versus Letrozole in Subjects With Estrogen/Progesterone Receptor- Positive Advanced or Metastatic Breast Cancer

Last checked: Nov 20, 2026Latest source record: Feb 24, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,286 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,286

Actual

Start

Dec 9, 2003

Primary completion

Jun 3, 2008

Study completion Mar 22, 2018

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Nov 26, 2003

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study evaluated and compared the efficacy and tolerability of lapatinib and letrozole, with letrozole and placebo in post-menopausal women with hormone receptor positive (ER positive and/or PgR positive) advanced or metastatic breast cancer, who had not received prior therapy for advanced or metastatic disease.

Conditions

  • Breast Neoplasms

Interventions

  • LapatinibDrug

    1500 mg orally once a day

  • LetrozoleDrug

    2.5 mg orally once a day

  • PlaceboDrug

    Placebo (which matched with lapatinib tablet)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Progression Free Survival (PFS) in the Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced or Metastatic Breast Cancer as Assessed by the InvestigatorTime frame: From the date of randomization until the date of the first documented progression or date of death from any cause, whichever came first, assessed for up to 46 months
  2. Progression Free Survival (PFS) of Participants in the HER2-Positive Population as Assessed by the InvestigatorTime frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 46 months

Locations

278 sites in 29 countries. Site status is shown where the registry gives one.

  • Novartis Investigative Site

    Tucson, Arizona

  • Novartis Investigative Site

    Hot Springs, Arkansas

  • Novartis Investigative Site

    Jonesboro, Arkansas

  • Novartis Investigative Site

    Alhambra, California

  • Novartis Investigative Site

    Bakersfield, California

  • Novartis Investigative Site

    Duarte, California

  • Novartis Investigative Site

    Fountain Valley, California

  • Novartis Investigative Site

    Fresno, California

  • Novartis Investigative Site

    Fullerton, California

  • Novartis Investigative Site

    La Jolla, California

  • Novartis Investigative Site

    Long Beach, California

  • Novartis Investigative Site

    Los Angeles, California

  • Novartis Investigative Site

    Montebello, California

  • Novartis Investigative Site

    Northridge, California

  • Novartis Investigative Site

    Oxnard, California

  • Novartis Investigative Site

    Pleasant Hill, California

  • Novartis Investigative Site

    Porterville, California

  • Novartis Investigative Site

    Redondo Beach, California

  • Novartis Investigative Site

    San Diego, California

  • Novartis Investigative Site

    Santa Barbara, California

  • Novartis Investigative Site

    Santa Maria, California

  • Novartis Investigative Site

    Vallejo, California

  • Novartis Investigative Site

    Vista, California

  • Novartis Investigative Site

    Aurora, Colorado

  • Novartis Investigative Site

    Denver, Colorado

  • Novartis Investigative Site

    Longmont, Colorado

  • Novartis Investigative Site

    Wheat Ridge, Colorado

  • Novartis Investigative Site

    New Haven, Connecticut

  • Novartis Investigative Site

    Boca Raton, Florida

  • Novartis Investigative Site

    Boca Raton, Florida

  • Novartis Investigative Site

    Gainesville, Florida

  • Novartis Investigative Site

    Gainesville, Florida

  • Novartis Investigative Site

    Hollywood, Florida

  • Novartis Investigative Site

    Lakeland, Florida

  • Novartis Investigative Site

    Miami, Florida

  • Novartis Investigative Site

    Orlando, Florida

  • Novartis Investigative Site

    Port Saint Lucie, Florida

  • Novartis Investigative Site

    West Palm Beach, Florida

  • Novartis Investigative Site

    Atlanta, Georgia

  • Novartis Investigative Site

    Marietta, Georgia

Showing 40 of 278 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.